Skip to content

Ketamine: all studies

Page 192 of 449: studies 1,911 to 1,920 of 4,483, newest first. Back to the ketamine overview

Research

Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in Adult Hippocampus

Biological Psychiatry June 1, 2022 Yukitoshi Izumi, F. Hsu, C. Conway et al.

BACKGROUND: Nitrous oxide (N2O) is a non-competitive inhibitor of NMDA receptors (NMDARs) that appears to have ketamine-like rapid antidepressant effects in patients with treatment resistant major depression. In preclinical studies, ketamine enhances glutamate-mediated synaptic transmission in hippocampus and prefrontal cortex. The present study examined effects of N2O on glutamate transmission...

Cortical Acetylcholine Levels Correlate With Neurophysiologic Complexity During Subanesthetic Ketamine and Nitrous Oxide Exposure in Rats.

Anesthesia & Analgesia June 1, 2022 Michael A. Brito, Duan Li, Christopher W Fields et al.

Neurophysiologic complexity has been shown to decrease during states characterized by a depressed level of consciousness, such as sleep or anesthesia. Conversely, neurophysiologic complexity is increased during exposure to serotonergic psychedelics or subanesthetic doses of dissociative anesthetics. However, the neurochemical substrates underlying changes in neurophysiologic complexity are...

Combined Low Dose of Ketamine and Social Isolation: A Possible Model of Induced Chronic Schizophrenia-Like Symptoms

European Psychiatry June 1, 2022 D. Khalifa, L. Rashed, A. Shamseldeen et al.

Introduction Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model...

[Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide].

L'Encephale June 1, 2022 Hugo Bottemanne, A Baldacci, C Muller et al. 7 citations

Ketamine, a non-competitive NMDA receptor antagonist, is used as a fast-acting antidepressant therapy in depressive disorders. This treatment provokes dissociative effects associating derealization and depersonalization, and a synaptogenic signaling cascade promoting brain plasticity. Despite several preliminary studies suggesting the usefulness of its combination with psychotherapy,...

DOI: 10.1016/j.encep.2021.08.011 (opens in new tab) Full text (opens in new tab) Antidepressant Antidépresseur Augmented psychotherapy Belief updating +9

S-Ketamine in the treatment of depressive emergencies: a cases series of patients in a suicidal crisis

European Psychiatry June 1, 2022 Bernhard T Baune, Z. Susam, V. Falcone et al.

Introduction Psychiatric emergencies in Major Depressive Disorder (MDD) are characterised by multiple types of symptoms including risk of self-harm and suicidal ideation. S-ketamine intranasally (Spravato) has recently been shown to help alleviate symptoms during depressive emergencies. In this case-series, we detail the clinical effects and usability of S-ketamine applied intranasally in a...

Ketamine As A New Therapeutic Option For The Management Of Mental Disorders

European Psychiatry June 1, 2022 M. Turki, O. Abidi, S. Ellouze et al. 1 citation

Introduction Ketamine is routinely used for anesthetic induction because of its dissociative properties. Recently, it has attracted attention as a rapid-acting anti-depressant, but other studies have also reported its efficacy in the management of diverse psychiatric pathologies previously resistant to treatment. Objectives We aimed to review the efficacity of ketamine in the management of...

Ketamine and Electroconvulsive Therapy: Better Together?

European Psychiatry June 1, 2022 A. Fraga, B. Mesquita, João Facucho-Oliveira et al.

Introduction Major depressive disorder (MDD) is a highly prevalent clinical condition with a leading cause of disability worldwide. The currently available therapeutic agents have important limitations regarding side effects, partial or non-responsiveness. Patients are considered to have treatment-resistant depression (TRD) if there is no effect or minimal effectiveness after receiving adequate...

Therapy group following a Ketamine treatment – a case report of a patient with resistant depression

European Psychiatry June 1, 2022 H. Yaniv, V. Savlev

Introduction There are some patients that remain resistant to treatment for major depressive disorder - who were treated with two or more different medications, and did not demonstrate any improvement in their mental-state. These patients can be treated with a new treatment – Esketamine. The recommended Esketamine treatment protocol includes 8-treatment sessions, each session lasts about two...

Structure identification and analysis of the suspected chemical precursor of 2-fluorodeschloroketamine and its decomposition products.

Drug Testing and Analysis June 1, 2022 Xuan Luo, Di Zhang, Qiulian Luo et al. 4 citations

In this work, 1-[(2″-fluorophenyl)(methylimino)methyl]cyclopentan-1-ol (2-fluorodeschlorohydroxylimine) was identified as a suspected chemical precursor of 2-fluorodeschloroketamine (2-FDCK) using gas chromatography-mass spectrometry (GC-MS) and gas chromatography-quadrupole/time-of-flight mass spectrometry (GC-Q/TOF-MS) and comparing the data with those of ketamine and its chemical precursor,...

DOI: 10.1002/dta.3229 (opens in new tab) Full text (opens in new tab) 2-fluorodeschlorohydroxylimine Analytical method Decomposition pathway Fragmentation +1

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature

Journal of Pain Research June 1, 2022 Sandra J Drozdz, Akash Goel, Matthew W Mcgarr et al. 2 citations

Sandra J Drozdz,1 Akash Goel,1– 3 Matthew W McGarr,4 Joel Katz,3,5– 7 Paul Ritvo,5,7 Gabriella F Mattina,1 Venkat Bhat,8– 10 Calvin Diep,3 Karim S Ladha1,3,10 1Department of Anesthesia, St. Michael’s Hospital, Toronto, ON, Canada; 2Department of Anesthesiology, Pain and Perioperative Medicine, Stanford University, Stanford, CA, USA; 3Department of Anesthesiology and Pain Medicine,...

DOI: 10.2147/jpr.s360733 (opens in new tab) Ketamine Anxiety Narrative review Psychotherapist +4